Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-06-18

Clinical Trial Update: Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke [Phase 2]

View source ↗

Summary

Phase 2 trial update on Trans Sodium Crocetinate (TSC) for suspected acute stroke was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trans Sodium Crocetinate (trans-sodium crocetinate)

Snippet

Sponsor: Diffusion Pharmaceuticals Inc | Conditions: Stroke, Acute | Phase 2 | Status: TERMINATED | Results posted: 2021-06-18